News · 26 weeks61+400%
2026-04-192026-10-11
Mix3190d
- Insider9(29%)
- Other6(19%)
- SEC Filings6(19%)
- Analyst5(16%)
- Earnings4(13%)
- Offering1(3%)
Latest news
25 items- ANALYSTUBS initiated coverage on Nektar Therapeutics with a new price targetUBS initiated coverage of Nektar Therapeutics with a rating of Neutral and set a new price target of $53.00
- ANALYSTLeerink Partners initiated coverage on Nektar Therapeutics with a new price targetLeerink Partners initiated coverage of Nektar Therapeutics with a rating of Outperform and set a new price target of $130.00
- ANALYSTRaymond James initiated coverage on Nektar TherapeuticsRaymond James initiated coverage of Nektar Therapeutics with a rating of Mkt Perform
- PR/UPDATE -- Nektar Therapeutics/In the news release, New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026, issued 01-Oct-2026 by Nektar Therapeutics over PR Newswire, formatting irregularities were introduced by PR Newswire in error throughout the release upon distribution. The complete, corrected release follows:New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026Rezpegaldesleukin demonstrated durability and deepening of response through one year of treatment in two dermatological indications, reinforcing the di
- SECNektar Therapeutics filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)
- PRNew Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026Rezpegaldesleukindemonstrateddurabilityanddeepeningofresponsethroughone year of treatment in two dermatological indications, reinforcing the differentiated properties of this novel Treg mechanismIn alopecia areata patients, SALT Score ≤20 response maintained in 75% at 4 months off treatment and in 63% at six months off treatmentHair regrowth continued for 6 months off treatment with 19% of patients achieving SALT Score ≤10, an improvement from 7% at the end of 52 weeks of treatmentThird Phase 3 study in the global ZENITH AD program initiated, expanding the program into treatment-experiencedatopicdermatitispatients; Phase3ZENITHAAstudytoinitiate in early 2027Companytohostconferencecallwithinv
- PRNew Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic DermatitisRezpegaldesleukin-associated improvements were detected as early as Week 2 and were significantly correlated with subsequent clinical responseSAN FRANCISCO and VIENNA, Sept. 30, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) and collaborators at the Icahn School of Medicine at Mount Sinai today announced new results from a multi-omic biomarker sub-study from REZOLVE-AD providing further evidence that rezpegaldesleukin engages its regulatory Tcell (Treg)-mediated mechanism in patients with moderate-to-severe atopic dermatitis, with significant biomarker changes associated with clinical improvement observed as early as Week 2.Rezpegaldesleukin is an investigational first-in-class Treg
- PRNektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026New data to be presented from the REZOLVE-AA study at EADV, including 6-month off-treatment data for patients with severe-to-very-severe alopecia areataCompany to host conference call with investors and analysts on October 1, 2026 at 8:00 AM ET/2:00 PM CETSAN FRANCISCO, Sept. 28, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that data from its Phase 2b studies of rezpegaldesleukin in atopic dermatitis and alopecia areata will be presented in three separate oral presentations at the European Academy of Dermatology & Venereology (EADV) Congress 2026, to take place September 30 to October 3, 2026, in Vienna, Austria.
- INSIDERDirector Whitfield Roy A was granted 2,000 shares, increasing direct ownership by 14% to 16,417 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- INSIDERDirector Greer R Scott was granted 2,000 shares, increasing direct ownership by 10% to 22,239 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- INSIDERDirector Brainard Diana was granted 2,000 shares, increasing direct ownership by 105% to 3,904 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- INSIDERDirector Chess Robert was granted 2,000 shares, increasing direct ownership by 12% to 19,019 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- INSIDERDirector Ajer Jeffrey Robert was granted 2,000 shares, increasing direct ownership by 88% to 4,277 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- PRNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN FRANCISCO, Sept. 25, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that, on September 18, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 58,600 shares of its common stock and 2,450 restricted stock units (RSUs) to eleven newly-hired employees under Nektar's 2025 Inducement Plan. Nektar's 2025 Inducement Plan was adopted by its Board of Directors on November 6, 2025 and is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Nektar
- SECNektar Therapeutics filed SEC Form 8-K: Other Events8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)
- SECNektar Therapeutics filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)
- PRNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN FRANCISCO, Aug. 28, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that, on August 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 25,200 shares of its common stock and 5,000 restricted stock units (RSUs) to eleven newly-hired employees under Nektar's 2025 Inducement Plan. Nektar's 2025 Inducement Plan was adopted by its Board of Directors on November 6, 2025 and is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Nektar (or
- PRNektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic DermatitisREZOLVE-AD study met all primary and key secondary endpoints, including EASI-75, EASI-90, Itch NRS, vIGA-AD and BSA, on rezpegaldesleukin 24 µg/kg q2wFirst large, placebo-controlled trial to support T-reg modulation as a clinical mechanism for immunoregulation of chronic inflammatory diseaseFindings support the continued development of rezpegaldesleukin in the ongoing Phase 3 ZENITH AD clinical programSAN FRANCISCO, Aug. 25, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced the publication of peer-reviewed data from the 16-week induction period of REZOLVE-AD, a global, randomized, double-blind, placebo-controlled Phase 2b study evaluating rezpegaldesleukin in adults with
- ANALYSTAnalyst resumed coverage on Nektar Therapeutics with a new price targetAnalyst resumed coverage of Nektar Therapeutics with a rating of Neutral and set a new price target of $65.00
- INSIDERChief R&D Officer Zalevsky Jonathan sold $13,388 worth of shares (186 units at $71.98), decreasing direct ownership by 2% to 9,570 units (SEC Form 4) (withholding obligation)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- INSIDERPresident & CEO Robin Howard W sold $30,088 worth of shares (418 units at $71.98), decreasing direct ownership by 0.76% to 54,627 units (SEC Form 4) to satisfy tax liability4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- SECSEC Form S-8 filed by Nektar TherapeuticsS-8 - NEKTAR THERAPEUTICS (0000906709) (Filer)
- SECSEC Form 10-Q filed by Nektar Therapeutics10-Q - NEKTAR THERAPEUTICS (0000906709) (Filer)
- SECNektar Therapeutics filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)
- PRNektar Therapeutics Announces Second Quarter 2026 Financial ResultsSAN FRANCISCO, Aug. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today reported financial results for the second quarter ended June 30, 2026. Cash and investments in marketable securities on June 30, 2026, were $1,023.4 million as compared to $245.8 million on December 31, 2025. "This year continues to be a transformative year for Nektar as we advance our lead program, rezpegaldesleukin, into Phase 3 clinical trials," said Howard W. Robin, President and Chief Executive Officer of Nektar. "We initiated the first Phase 3 ZE
NKTR FAQ
6 questionsWhat does Nektar Therapeutics do?
Nektar Therapeutics operates as a biopharmaceutical company. The company researches and develops pipeline of investigational medicines in oncology, immunology, and virology, as well as a portfolio of approved partnered medicines. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma and urothelial cancer; phase 1/2A clinical trial to...Where does NKTR stock trade?
Nektar Therapeutics (NKTR) is listed on NASDAQ.What sector and industry is NKTR in?
Nektar Therapeutics operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about NKTR?
Nektar Therapeutics has had 8 recent analyst actions on file. The most recent action was from UBS: Neutral on 2026-10-12.What companies are similar to NKTR?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare NKTR side-by-side with any of them on Quantisnow.How can I track NKTR on Quantisnow?
Quantisnow aggregates Nektar Therapeutics's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NKTR to receive live email and push alerts on every new disclosure.